Chemclin Diagnostics announced that shareholder CICC Kangrui reduced its stake by 2.66 million shares through centralized competitive trading, accounting for 0.67% of the company's total share capital, bringing its holding down to 4.99%. The share reduction plan has now been fully implemented. The company reported first-quarter 2026 revenue of 73.35 million yuan and a net profit attributable to the parent company of 8.96 million yuan.
Chemclin Diagnostics Co. Ltd. ACICC Kangrui reduced its stake by 2.66 million shares, now below 5%.
Zhuhai Comleader Information Science & Technology Co. Ltd. A